Nangibotide is a 12-amino-acid synthetic peptide built to dampen TREM-1, a receptor that amplifies inflammation in immune cells. It has been tested mainly in septic shock and severe COVID-19. This guide covers its structure, mechanism, trials, reported side effects and status. Sources were checked on November 17, 2026.
Quick answer: Nangibotide, also called LR12 or Motrem, is a TREM-1 inhibitor from the French company Inotrem. It acts as a decoy that blocks TREM-1 activation. Phase 2 trials in septic shock showed no significant benefit on organ failure scores. It is not FDA-approved.
Vitrapep does not sell nangibotide; this page is a reference summary of published research and regulatory information.
What is nangibotide?
Nangibotide is a short linear peptide. Its first human study describes it as “a chemically synthesized peptide, derived from the protein TREM-like transcript-1 (TLT-1).” It “is composed of 12 L-amino-acids” (Cuvier et al., 2018). TLT-1 is a natural protein related to TREM-1. Our primer on what peptides are explains how such short chains are made.
PubChem lists the formula as C54H83N15O21S2 and the molecular weight as 1,342.5 g/mol (PubChem CID 165360157). Earlier papers call it LR12, and early trial records call it Motrem.
Nangibotide: key facts
| Fact | Detail |
|---|---|
| Structure type | Linear synthetic peptide, 12 L-amino acids, derived from TLT-1 |
| Class | TREM-1 inhibitor (decoy receptor) |
| Molecular formula | C54H83N15O21S2 |
| Molecular weight | 1,342.5 g/mol |
| Development stage | Phase 2b in septic shock (primary analysis published 2023); Phase 3 design agreed with FDA (2024) |
| Sponsor or developer | Inotrem (Paris, France) |
How does nangibotide work?
TREM-1 stands for triggering receptor expressed on myeloid cells 1. It is found on myeloid immune cells. The first human study calls TREM-1 “an amplifier of the innate immune response by synergizing with toll-like receptors.” The ASTONISH protocol paper describes nangibotide as “a novel regulator of the TREM-1 pathway” (François et al., 2021).
Nangibotide “inhibits TREM-1 activation by acting as a decoy receptor” (Cuvier et al., 2018). A decoy soaks up the signals that would otherwise switch the receptor on. In a monkey study of endotoxin exposure, LR12-treated animals “remained normotensive,” and LR12 “attenuated cytokine production” (Derive et al., 2014). Our explainer on how peptides work covers receptor signaling in general.
What is nangibotide being studied for?
Nangibotide is not approved by the FDA for any use. ClinicalTrials.gov lists four Inotrem studies.
- healthy male volunteers, Phase 1 (NCT03463044, completed 2016);
- septic shock, Phase 2a, 50 enrolled (NCT03158948, completed 2018);
- COVID-19 patients receiving ventilatory support, Phase 2, ESSENTIAL (NCT04429334, completed 2022); and
- septic shock, Phase 2b, ASTONISH, 355 enrolled (NCT04055909, listed as active, not recruiting).
In January 2024, Inotrem said FDA accepted its plan for one Phase 3 registration trial, called ACCURATE. It would enroll about 1,300 septic shock patients, with a primary analysis group of 900 selected by high blood sTREM-1 (Inotrem, 2024). We found no ACCURATE record on ClinicalTrials.gov.
What did the key trials show?
ASTONISH (Phase 2b, septic shock). This double-blind human trial analyzed 355 patients: 116 on placebo and 239 across two nangibotide groups. The primary outcome was the change in SOFA organ failure score to day 5. The authors stated it “did not achieve the primary outcome of improvement in SOFA score at the predefined sTREM-1 value” (François et al., 2023a). Day-28 mortality was 25% on placebo and 32% and 25% in the two nangibotide groups.
ESSENTIAL (Phase 2, COVID-19). This double-blind human trial recruited 220 patients and was stopped early because of slow recruitment. Clinical status improved by day 28 in 64.7% on nangibotide and 52.0% on placebo (odds ratio 1.79; p = 0.043). Day-28 mortality was 16.0% and 28.0% (François et al., 2023b). In the planned high sTREM-1 subgroup, the result was not significant (p = 0.063).
Phase 2a (septic shock). This trial randomized 49 patients. Its primary goals were safety and drug levels. Changes in SOFA score did not differ significantly from placebo (François et al., 2020).
What side effects have studies reported?
In healthy volunteers, the authors reported only a few adverse events. They were “mild in severity and considered unrelated to treatment” (Cuvier et al., 2018). That study randomized 27 healthy subjects.
In ASTONISH, treatment-emergent adverse events occurred in nearly all patients: 96% on placebo and 96% and 95% on nangibotide. Serious events occurred in 24% on placebo and 22% and 26% on nangibotide. The Phase 2a trial found no significant increase in such events, and no anti-drug antibodies. In ESSENTIAL, event rates were similar between groups.
What is nangibotide’s regulatory status, and how is it used in research?
Nangibotide is an investigational drug. Inotrem’s 2024 release describes FDA acceptance of its biomarker-driven Phase 3 design. We did not find an fda.gov page on nangibotide, and we found no FDA warning about it.
In research, LR12 is used as a tool to block TREM-1 in animal models, such as the monkey endotoxin study above. A 2025 paper described a mechanism-based prognostic enrichment strategy for future nangibotide trials in septic shock (François et al., 2025). Other immune-modulating peptides include thymosin alpha 1 and aviptadil.
Frequently asked questions about nangibotide
Is nangibotide a peptide?
Yes. It is a chemically synthesized chain of 12 L-amino acids derived from the protein TLT-1.
Is nangibotide FDA-approved?
No. It has been tested only in clinical trials. In 2024, its developer announced FDA agreement on a Phase 3 design.
What is TREM-1?
It is a receptor on myeloid immune cells that amplifies innate immune responses, working together with toll-like receptors.
Are LR12, Motrem and nangibotide the same?
Yes. LR12 is the research name and Motrem appears in early trial titles, such as NCT03158948.
Did nangibotide work in septic shock?
The Phase 2b ASTONISH trial did not meet its primary outcome on organ failure scores at day 5.
What to know now
- Structure: 12 L-amino acids from TLT-1; C54H83N15O21S2; 1,342.5 g/mol.
- Mechanism: decoy receptor that inhibits TREM-1 activation.
- Evidence: ASTONISH missed its primary outcome; ESSENTIAL in COVID-19 was small and stopped early.
- Safety: adverse event rates similar to placebo in Phase 2 trials.
- Status: not FDA-approved; Phase 3 design agreed with FDA in 2024, per Inotrem.